WSLGYTG peptide

WSLGYTG is a synthetic peptide identified through phage display biopanning that specifically targets the extracellular domain of Programmed cell death-ligand 1 (PD-L1). In the context of advanced cancer immunotherapy, this peptide is genetically engineered onto the surface of filamentous phages (such as fd phages) to serve as a targeting and therapeutic agent. By binding to PD-L1 on tumor cells, WSLGYTG blocks the PD-1/PD-L1 checkpoint pathway, which is a common mechanism used by cancers to evade the immune system. Preclinical studies published in 2024 demonstrate that phages displaying WSLGYTG can effectively home to melanoma tissues and trigger targeted immunotherapy, resulting in significant tumor reduction without the systemic side effects often associated with non-targeted PD-L1 inhibitors. The peptide is typically fused to the major coat proteins of the phage to create multivalent bionanofibres that enhance binding affinity and therapeutic efficacy.

Other names

PD-L1-binding peptidePD-L-1-binding peptidePD-L 1-binding peptide